Continuous CSF and plasma sampling method for amyloid biological variability in healthy volunteers and patients with Alzheimer*s disease.

Continuous CSF and plasma sampling method for amyloid biological variability in healthy volunteers and patients with Alzheimer*s disease. - Alzheimer-liquor study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32144

Enrollment

Registered

2008-12-15

Start date

2009-01-05

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease Dementia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: ad 1. Healthy elderly volunteers, aged 50 yrs and over ad 2. Patients 50 years or older with mild stage Alzheimer's disease (diagnosed accoring to the internationally accepted NINDS-ADRDA criteria, mild stage: CDR, clinical dementia rating = 1)

Exclusion criteria

Exclusion criteria: 1. Usage of: a. Anticoagulants (low molecular heparines, acenocoumarol derivates), b. thrombocyte aggregration inhibitors (acetylsalicylic acid, carbasalaat calcium, clopidrogel, dipyridamol) c. NSAIDs that cannot be stopped during the study 2. allergy to epidural or other anaesthetics 3. intracerebral mass, as diagnosed by CT or MRI before the study 4. other neurological diseases 5. incapable to consent for the study (judged accoring to the procedure proposed by vd Vorm & Olde Rikkert, 2008, Competence assessment in Dementia; Springer Verlag, Wien; p 85-92) 6. Subjects with a contraindication for a spinal catheter

Design outcomes

Primary

Measure	Time frame
CSF and serum concentration of beta amyloid in time. CSF and serum amyloid concentrations.	—

Secondary

Measure	Time frame
Tau and phospotau in CSF and serum in time	—

Countries

Netherlands

Outcome results